

Attorney Docket No. 36290-0415-00-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
ACTING AS THE DESIGNATED/ELECTED OFFICE

In Re Patent Application Of: Patrick Gerard JOHNSTON; Daniel LONGLEY

Application No.: Not Yet Assigned
(International Application No. PCT/GB2004/005006)

Filing Date: --
(International Filing Date: 26 November 2004 (26.11.2004))

Customer No.: 23973


Invention: CANCER TREATMENT

INFORMATION DISCLOSURE STATEMENT

MAIL STOP PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The present application is a 371 of PCT/GB2004/005006. Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith in duplicate is a substitute PTO Form 1449 listing the references cited in the Search Report in the international phase. It is believed that copies of the references have been or will be forwarded by the International Search Authority. Examiner is encouraged to contact the undersigned if reference copies have not been received.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10	
EXPRESS MAIL Mailing Label No:	EV 545927615 US
Date of Deposit:	26 May 2006
<p>I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL-POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p>	
 Signature of person mailing page:	
Leola P. Goodman Type or print name of person	

The Examiner is respectfully requested to review the items listed on the PTO Form 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute Form 1449, and return one copy to the undersigned.

This Information Disclosure Statement should not be construed as a representation that the cited references are material or that more references do not exist.

This statement is being submitted before receipt of any office action on the merits. Thus, no fee is due for the filing of this paper. However, if a fee is due, please charge deposit account 50-0573.

Respectfully submitted,

PATRICK GERARD JOHNSTON, et al.

BY


DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
TEL: (215) 988-3312
FAX: (215) 988-2757
Attorney for Applicants

AP20 Rec'd PCT/PTO 26 MAY 2006

SHEET 1 OF 2

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO. 36290-0415-00-US	INTERNATIONAL SERIAL NO. PCT/GB2004/005006
	FILING DATE --	U.S. SERIAL NO. 6/580748 Not Yet Assigned
	APPLICANT(S): Patrick Gerard JOHNSTON, et al.	
	INTERNATIONAL FILING DATE: November 26, 2004	GROUP ART UNIT: Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
/R.S./	AA WO 03/035868 A	05/01/2003	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/R.S./	AB	HYER, M.L. et al., "Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis" <i>CANCER BIOLOGY & THERAPY</i> , Vol. 1:4 (July 2002) pp. 401-406
/R.S./	AC	USLU, R. et al., "Chemosensitization of human prostate carcinoma cell lines to anti-Fas-mediated cytotoxicity and apoptosis" <i>CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US</i> , Vol. 3:6 (June 1997) pp. 963-972
/R.S./	AD	THEARD, D. et al., "Etoposide and Adriamycin but not Genistein can activate the checkpoint kinase Chk2 independently of ATM/ATR" <i>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS</i> , Vol. 289 (2001) pp. 1199-1204
/R.S./	AE	GUROVA, K.V. et al., "Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells" <i>CANCER RESEARCH</i> , Vol. 63 (June 1 2003) pp. 2905-2912
/R.S./	AF	IWASE, M. et al., "Enhanced susceptibility of oral squamous cell carcinoma cell lines to Fas-mediated apoptosis by Cisplatin and 5-Fluorouracil" <i>INTERNATIONAL JOURNAL OF CANCER</i> , Vol. 106 (Sep 10 2003) pp. 619-625
/R.S./	AG	WAKASA, T. et al., "The combination of ionizing radiation and expression of a wild type p53 gene via recombinant adenovirus induced a prominent tumor suppressing effect in human oral squamous cell carcinoma" <i>THE BRITISH JOURNAL OF RADIOLOGY</i> , Vol. 75 (2002) pp. 657-662
/R.S./	AH	SIEGMUND, D. et al., "Selective inhibition of FLICE-like Inhibitory Protein (FLIP) expression with small interfering RNA oligonucleotides (siRNAs) is sufficient to sensitize tumor cells for TRAIL-induced apoptosis" <i>MOLECULAR MEDICINE, BLACKWELL SCIENCE, CAMBRIDGE, MA, US</i> , Vol. 8:11 (Nov 2002) pp. 725-732
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

PHIP480077\1

APPROVED 28 MAY 2006

SHEET 2 OF 2

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO. 36290-0415-00-US	INTERNATIONAL SERIAL NO. PCT/GB2004/005006
	FILING DATE 10/5/2004	US SERIAL NO. Not Yet Assigned
	APPLICANT(S): Patrick Gerard JOHNSTON, et al.	
	INTERNATIONAL FILING DATE: November 26, 2004	GROUP ART UNIT: Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/R.S./	AI	DATABASE EMBL-EBI "Homo sapiens FLICE-like inhibitory protein long form mRNA, complete cds." Database accession no. U97074 (July 1, 1999)
/R.S./	AJ	KAMARAJAN, P. et al., "Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signaling" <i>BIOCHEMICAL JOURNAL</i> , Vol. 376:1 (Nov 15 2003) pp. 253-260
/R.S./	AK	MAY, E. et al., "Endogenous HeLa p53 proteins are easily detected in HeLa cells transfected with mouse deletion mutant p53 gene" <i>ONCOGENE</i> , Vol. 6:8 (1991) pp. 1363-1366
/R.S./	AL	PEDERSEN, I.M. et al., "The triterpenoid CDDO induces apoptosis in refractory CLL B cells" <i>BLOOD</i> , Vol. 100:8 (Oct 15 2002) pp. 2965-2972
/R.S./	AM	POULAKI, V. et al., "Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and bc1-2" <i>CANCER RESEARCH</i> , Vol. 61 (June 15 2001) pp. 4864-4872
/R.S./	AN	MICHEAU, O., "Cellular FLICE-inhibitory protein: an attractive therapeutic target?" <i>EXPERT OPINION ON THERAPEUTIC TARGETS, ASHLEY PUBLICATIONS, LONDON, GB</i> , Vol. 7:4 (Aug 2003) pp. 559-573

EXAMINER /Richard Schnizer/	DATE CONSIDERED 09/19/2008
--------------------------------	-------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1AP20 RECEIVED PTO 26 MAY 2006

SHEET 1 OF 2

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO. 36290-0415-00-US	INTERNATIONAL SERIAL NO. PCT/GB2004/005006
	FILING DATE —	U.S. SERIAL NO. Not Yet Assigned
	APPLICANT(S): Patrick Gerard JOHNSTON, et al.	
	INTERNATIONAL FILING DATE: November 26, 2004	GROUP ART UNIT: Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
AA WO 03/035868 A	05/01/2003	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AB	HYER, M.L. et al., "Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis" <i>CANCER BIOLOGY & THERAPY</i> , Vol. 1:4 (July 2002) pp. 401-406
AC	USLU, R. et al., "Chemosensitization of human prostate carcinoma cell lines to anti-Fas-mediated cytotoxicity and apoptosis" <i>CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US</i> , Vol. 3:6 (June 1997) pp. 963-972
AD	THEARD, D. et al., "Etoposide and Adriamycin but not Genistein can activate the checkpoint kinase Chk2 independently of ATM/ATR" <i>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS</i> , Vol. 289 (2001) pp. 1199-1204
AE	GUROVA, K.V. et al., "Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells" <i>CANCER RESEARCH</i> , Vol. 63 (June 1 2003) pp. 2905-2912
AF	IWASE, M. et al., "Enhanced susceptibility of oral squamous cell carcinoma cell lines to Fas-mediated apoptosis by Cisplatin and 5-Fluorouracil" <i>INTERNATIONAL JOURNAL OF CANCER</i> , Vol. 106 (Sep 10 2003) pp. 619-625
AG	WAKASA, T. et al., "The combination of ionizing radiation and expression of a wild type p53 gene via recombinant adenovirus induced a prominent tumor suppressing effect in human oral squamous cell carcinoma" <i>THE BRITISH JOURNAL OF RADIOLOGY</i> , Vol. 75 (2002) pp. 657-662
AH	SIEGMUND, D. et al., "Selective inhibition of FLICE-like Inhibitory Protein (FLIP) expression with small interfering RNA oligonucleotides (siRNAs) is sufficient to sensitize tumor cells for TRAIL-induced apoptosis" <i>MOLECULAR MEDICINE, BLACKWELL SCIENCE, CAMBRIDGE, MA, US</i> , Vol. 8:11 (Nov 2002) pp. 725-732

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

18/580748 28 MAY 2006

18/580748

SHEET 2 OF 2

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO. 36290-0415-00-US	INTERNATIONAL SERIAL NO. PCT/GB2004/005006
	FILING DATE --	U.S. SERIAL NO. Not Yet Assigned
	APPLICANT(S): Patrick Gerard JOHNSTON, et al.	
	INTERNATIONAL FILING DATE: November 26, 2004	GROUP ART UNIT: Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AI	DATABASE EMBL-EBI "Homo sapiens FLICE-like inhibitory protein long form mRNA, complete cds." Database accession no. U97074 (July 1, 1999)
AJ	KAMARAJAN, P. et al., "Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signaling" <i>BIOCHEMICAL JOURNAL</i>, Vol. 376:1 (Nov 15 2003) pp. 253-260
AK	MAY, E. et al., "Endogenous HeLa p53 proteins are easily detected in HeLa cells transfected with mouse deletion mutant p53 gene" <i>ONCOGENE</i>, Vol. 6:8 (1991) pp. 1363-1366
AL	PEDERSEN, I.M. et al., "The triterpenoid CDDO induces apoptosis in refractory CLL B cells" <i>BLOOD</i>, Vol. 100:8 (Oct 15 2002) pp. 2965-2972
AM	POULAKI, V. et al., "Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and bcl-2" <i>CANCER RESEARCH</i>, Vol. 61 (June 15 2001) pp. 4864-4872
AN	MICHEAU, O., "Cellular FLICE-inhibitory protein: an attractive therapeutic target?" <i>EXPERT OPINION ON THERAPEUTIC TARGETS</i>, ASHLEY PUBLICATIONS, LONDON, GB, Vol. 7:4 (Aug 2003) pp. 559-573

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.